Download Databook
Download Sample
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global single-cell omics market size is calculated at US$ 1.94 in 2024, grew to US$ 2.35 billion in 2025, and is projected to reach around US$ 12.05 billion by 2034. The market is expanding at a CAGR of 16.14% between 2025 and 2034.
DNA is the primary subject of single-cell genomics. In situations where just a small number of cells are available for investigation, it might be utilized, for instance, to investigate DNA heterogeneity in cell populations. DNA methylation and, consequently, gene control in individual cells are investigated by the area of single-cell epigenomics. One of the main drivers behind the introduction of single-cell genomic analysis has been the explosive expansion of next-generation sequencing (NGS) and third-generation sequencing's users, technology, and applications. Because single-cell omics technologies offer high-resolution insights into the complexity and heterogeneity of cells, they have completely changed molecular profiling.
In April 2025, the Department of Health-Abu Dhabi and Abu Dhabi Investment Office signed an agreement with GSK to establish a multi-omics research institute. This partnership aims to accelerate precision medicine and genomic science. This new institute will support the development of pioneering healthcare solutions and the generation of high-quality omics data.
A new age of biological study has been ushered in by the development of single-cell genomics, which has enabled scientists to thoroughly examine the complexities of cellular heterogeneity. The capacity of models powered by artificial intelligence (AI) to identify hidden patterns in single-cell expression data and classify different cell types according to gene expression profiles. A thorough understanding of cellular biology is provided by deep learning techniques in single-cell analysis. Researchers are able to extract valuable insights from intricate datasets by incorporating AI into single-cell data processing methods, which accelerates the advancement of scientific knowledge.
Rising Demand for Personalized Medicine
More precise and customized therapies can result from the important insights that individual cell molecular analysis can offer into the causes of illness. Additionally, single-cell omics is now more widely available and reasonably priced due to quick advancements in technology. For instance, researchers may now quickly generate a lot of data by examining hundreds of individual cells at once due to the advancement of high-throughput sequencing technology. Understanding the molecular processes at the heart of chronic illnesses like cancer and neurological issues is also becoming more and more important due to their rising incidence. It gives researchers an effective tool for single-cell disease pathophysiology research.
High Cost of Single-cell Omics
The high expense of single-cell analysis is a major market barrier for the single-cell omics industry. The costs associated with setting up and carrying out single-cell investigations can be major obstacles to the broad adoption of single-cell omics technologies, despite the tremendous potential insights and advantages they provide. Costs include several expenses, such as investing in specialized equipment, buying reagents, maintaining the machinery, and hiring qualified staff who can do intricate studies and interpret results. These budgetary factors may provide difficulties for startups, academic labs, and smaller research organizations with constrained funding, which would reduce the single-cell omics market demand.
Advancements in Omics Technology
By transforming molecular profiling, recent developments in single-cell omics technologies provide a substantial chance for commercial expansion. These state-of-the-art methods go beyond the constraints of conventional bulk omics approaches to provide high-resolution insights into cellular heterogeneity and complexity. Single-cell omics investigations reveal a variety of cell types, dynamic cellular states, and uncommon cell populations with previously unheard-of sensitivity and precision by examining individual cells. As single-cell omics develops further, it creates new avenues for creativity and discovery across a range of industries, propelling market expansion and broadening its molecular profiling applications.
By product type, the single-cell genomics segment led the single-cell omics market with the largest share in 2024. With the emergence of this new science, which is appropriately named single-cell genomics, researchers may now examine the whole complement of DNA (or even RNA) found in a single cell. In fact, the technology changed several biological study domains once Next Generation Sequencing was incorporated. Applications for the approach are many and include germline transmission, immunology, organogenesis, embryogenesis, tissue mosaicism, cancer, prenatal diagnostics, microbiology, and neuroscience.
By product type, the single-cell metabolomics segment is estimated to grow at a significant rate in the single-cell omics market during the forecast period. Mass spectrometry combined with single-cell metabolomics allows for the simultaneous detection of a wide range of metabolites from individual cells without the need for labeling or pre-selection, allowing for the mapping of phenotypes at the single-cell level. Despite being relatively new, the subject is rapidly developing due to a growing number of active research groups, methods for ionizing and collecting cells, data processing tools, and applications to address significant environmental and biological concerns.
By application, the oncology segment held the major share of the single-cell omics market in 2024 and is estimated to grow at the fastest CAGR during the forecast period. Because single-cell multi-omics technologies enable molecular analysis of individual cells, they have completely changed the field of cancer research. Single-cell multi-omics makes it possible to identify the heterogeneity inside tumors and comprehend the distinct molecular traits of various cell populations, in contrast to conventional bulk omics techniques that examine populations of cells collectively. Exciting opportunities will arise from single-cell omics technologies to analyze the functional and regulatory interactions of molecules both inside and across cells and to build a more comprehensive cell trajectory for comprehending the evolution of tumors.
By end-use, the academic and research organizations segment dominated the single-cell omics market in 2024. A collection of web-based platform technologies known as multi-omics portals helps researchers comprehend and obtain a more complete view of the single-cell omics data field. The use of single-cell omics has produced new resources, led to new discoveries, and is still influencing how researchers see stem cell biology, development, and other fields of study. High-throughput technologies have opened up fascinating new avenues for medical research and are becoming an increasingly significant part of biological researchers' daily work.
By end-use, the pharmaceutical and biotechnology companies segment is estimated to grow at the fastest rate in the single-cell omics market during the forecast period. Applications of transcriptomics and single-cell genomics are driving the creation of several new clinical and research fields in the pharmaceutical, therapeutic, and diagnostic sectors. These fields include developmental biology, evolutionary and comparative genomics, pharmacogenomics, gene therapy applications, and disease prevention. The use of single-cell technology significantly aided in the pharmacokinetic analysis, high-throughput screening, and target identification phases of the drug development process.
North America dominated the single-cell omics market share by 47% in 2024. Numerous internationally recognized academic and research institutes that have led the way in single-cell omics research are located in North America. These organizations are able to promote innovation in the sector because they have access to state-of-the-art resources, knowledge, and technology. The area is home to important centers for biotechnology and life sciences, including Boston, San Diego, and the San Francisco Bay Area. These centers encourage cooperation, funding, and the creation of innovative single-cell omics products and technologies. Additionally, a sizable number of pharmaceutical and biotechnology businesses based in this area are actively working to develop and market single-cell omics technologies for use in clinical and research settings.
NIH research is putting a lot of effort into figuring out how lifestyle and genes interact to impact people's lives and health. DNA is a household term because of fundamental research sponsored by the NIH that led to genetic engineering and the emergence of the $40 billion biotech sector. Every day, almost every pharmaceutical firm and biomedical research facility in the world harnesses the potential of the genetic revolution to uncover novel therapies and demythologize illnesses. The U.S. Food and Drug Administration (FDA) is considering modifying the labeling rules for significant medications that millions of Americans take as a result of the collective findings of research in this crucial field of biomedicine.
At the vanguard of the genomics revolution are Canadian academics, companies, and institutions, who are unleashing the science's promise to spur innovation across sectors, tackle global issues, and enhance people's quality of life. In 2024–2025, the Canadian government unveiled the Canadian Genomics Strategy, which is supported by a $175.1 million federal financing commitment spread over seven years. The Strategy will improve Canada's capacity to use genomics research in important industries.
Asia Pacific is estimated to host the fastest-growing single-cell omics market during the forecast period. The region's market is expected to be driven by factors including the growing burden of the target illness and the growing need for cutting-edge treatments. The region's market is expanding thanks to the growing interest of market participants in seizing unrealized market potential and their increased investments in the area. Furthermore, another possible reason propelling the regional market is the increasing agreements amongst businesses to fortify their market avenues.
In the past, China's research institutes were the primary sites for genomic and proteomic studies. Early on, the Chinese government recognized the promise of these technologies and offered financial assistance as well as supportive legislation. Development of reagents for measuring molecular events like intracellular pathways, cell signaling, and gene expression, as well as the creation of nucleic acid-based biochips that can be incorporated into next-generation diagnostic products, are among the current capabilities of Chinese companies engaged in genomic and proteomic research.
'One Day One Genome' is a project launched by the Department of Biotechnology (DBT) and the Biotechnology Research and Innovation Council (BRIC) to highlight India's vast microbiological potential. Genome sequencing will enable the general public to see the microbial world's untapped potential. The genome-encoded capabilities for several significant enzymes, antibiotic resistance, bioactive chemicals, etc., may be found by analyzing sequencing data. Better environmental management and protection, agricultural advancement, and human health enhancement are all benefits of this field of study.
Europe is expected to grow significantly in the single-cell omics market during the forecast period. Europe is right behind, with nations like Germany and the United Kingdom in the forefront. The need for single-cell omics technology is driven by the region's emphasis on customized healthcare and precision medicine. Market penetration is increased when industry participants and research institutes work together.
The importance of cutting-edge genomic technologies has grown in Germany despite a sluggish start. Genomic medicine will be implemented in Germany with the support of ongoing partnerships and regulatory evaluations, which will eventually improve the lives of patients. Additionally, some 500,000 people in Germany receive a cancer diagnosis each year. Significant progress has been made in early detection and treatment in the last several years and decades. In November 2024, German Cancer Aid gave 11.8 million euros over five years to the national research network "TACTIC" as part of its efforts to enhance cancer therapy in Germany. The 24 researchers working on the project are tasked with everything from preclinical research to the identification and development of novel active ingredients.
The strong government support and investment in research & infrastructure, including funding for research projects and establishing research centers, help in the market growth. For instance, the 100000 Genomes Project aims to make genomics part of routine healthcare and enhance genomic healthcare research. The well-established scientific community in metabolomics, genomics, and proteomics, and collaboration between healthcare providers, academia & industry help in the market growth. The growing demand for personalised healthcare & precision medicine, and technological advancement in single cell sequencing technology, drive market growth.
In October 2024, according to 10x Genomics' Chief Technology Officer and Founding Scientist, Michael Schnall-Levin, these releases are a crucial component of our continuous efforts to democratize single-cell analysis and make it more available and cheap for more academics than ever before. They are part of an expanding array of new single-cell products, protocols, and capabilities that will make 2024 the most innovative year for Chromium's platform. We look forward to seeing how laboratories of all sizes use our GEM-X portfolio's competitive performance, scalability, and affordability to support their research.
By Product Type
By Application
By End-User
By Region
June 2025
June 2025
June 2025
April 2025